Reproducibility of crackle counts in Bronchiectasis patients Source: International Congress 2019 – Respiratory function assessment in disease Year: 2019
Sputum eosinophilia in cryptogenic fibrosing alveolitis Source: Eur Respir J 2003; 22: Suppl. 45, 227s Year: 2003
Endothelin-1 in the exhaled breath condensate of patients with non-specific interstitial pneumonia (NSIP) and of patients with fibrosing alveolitis associated with systemic sclerosis (FASSc) Source: Eur Respir J 2002; 20: Suppl. 38, 226s Year: 2002
Clinical significance of morphological indexes of inflammation and sclerosis in idiopathic fibrosing alveolitis (IFA) and lung sarcoidosis Source: Eur Respir J 2002; 20: Suppl. 38, 107s Year: 2002
The features of the course of cryptogenic fibrosing alveolitis in women Source: Eur Respir J 2002; 20: Suppl. 38, 59s Year: 2002
Induced sputum neutrophilia and increased neurotrophin levels in patients with cryptogenic fibrosing alveolitis Source: Eur Respir J 2002; 20: Suppl. 38, 173s Year: 2002
Exhaled 8-isoprostane as a noninvasive marker of oxidative stress in patients with cryptogenic fibrosing alveolitis and fibrosing alveolitis associated with systemic sclerosis Source: Eur Respir J 2001; 18: Suppl. 33, 408s Year: 2001
Lung cancer in patients with cryptogenic fibrosing alveolitis Source: Annual Congress 2008 - Miscellaneous aspects of interstitial lung disease Year: 2008
Plasma fibronectin as the criterion of idiopathic fibrosing alveolitis severity Source: International Congress 2017 – IPF: from the bench to the bedside Year: 2017
MMPs in BAL from patients with scleroderma fibrosing alveolitis Source: Eur Respir J 2006; 28: Suppl. 50, 564s Year: 2006
Cytokine regulation in idiopathic fibrosing alveolitis (IFA) and lung sarcoidosis: clinicomorphological study Source: Eur Respir J 2001; 18: Suppl. 33, 107s Year: 2001
Impact of lymphocyte differential count in BALF on the mortality of patients with acute exacerbation of idiopathic chronic fibrosing interstitial pneumonia Source: International Congress 2016 – Clinical aspects of ILD Year: 2016
Clinical significance of different cytokines expression in lung tissue in idiopathic fibrosing alveolitis (IFA) and lung sarcoidosis Source: Eur Respir J 2002; 20: Suppl. 38, 313s Year: 2002
Longitudinal variability of pulmonary function and sputum eosinophilia in severe refractory asthmatics Source: Eur Respir J 2003; 22: Suppl. 45, 479s Year: 2003
The study of C5a complement component in patients with idiopathic pulmonary fibrosis, toxic fibrosing alveolitis and extrinsic allergic alveolitis Source: Eur Respir J 2001; 18: Suppl. 33, 108s Year: 2001
Analysis of IL-13 polymorphisms in patients with cryptogenic fibrosing alveolitis Source: Eur Respir J 2001; 18: Suppl. 33, 411s Year: 2001
Histopathological findings of biopsies from patients with extrinsic allergic alveolitis (hipersensitivity pneumonia) in subacute or chronic phase Source: Annual Congress 2013 –Diffuse parenchymal lung disease III Year: 2013
Serum KL-6 identifies ILD patients with a progressive fibrosing phenotype Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more Year: 2020
Association between monocyte count and ILD progression in subjects with fibrosing ILDs: data from the INBUILD trial Source: Virtual Congress 2021 – New approaches to diagnostic and prognostic evaluation of interstitial lung diseases of known causes Year: 2021
Parameters of antioxidant protection in patients with cryptogenic fibrosing alveolitis Source: Annual Congress 2007 - Considerations in the therapeutic approach of interstitial lung disease: oxidative stress and inflammation Year: 2007